theory clinical_79_2
imports Main

begin

typedecl entity
typedecl event

consts
  Patient :: "entity ⇒ bool"
  TNBC :: "entity ⇒ bool"
  Immunotherapy :: "entity ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  AppropriateFor :: "entity ⇒ entity ⇒ bool"
  Combination :: "entity ⇒ bool"
  Vemurafenib :: "entity ⇒ bool"
  MEKInhibitor :: "entity ⇒ bool"
  AvailableFor :: "entity ⇒ entity ⇒ bool"
  Carboplatin :: "entity ⇒ bool"
  Paclitaxel :: "entity ⇒ bool"
  AdvancedMelanoma :: "entity ⇒ bool"
  BRAFV600 :: "entity ⇒ bool"
  Activity :: "entity ⇒ bool"
  Tolerated :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Demonstrates :: "event ⇒ bool"
  PredominantlyIn :: "entity ⇒ event ⇒ bool"
  IrrespectiveOf :: "entity ⇒ event ⇒ bool"
  BRAF :: "entity ⇒ bool"
  MEKInhibitors :: "entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"
  Outcomes :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Improve :: "event ⇒ bool"
  SpecificallyFor :: "entity ⇒ event ⇒ bool"
  TreatedWith :: "entity ⇒ entity ⇒ bool"

(* Explanation 1: Patient with TNBC is not appropriate for immunotherapy or PARP inhibitors as second line therapy *)
axiomatization where
  explanation_1: "∀x y z. Patient x ∧ TNBC x ∧ (Immunotherapy y ∨ PARPInhibitors z) ⟶ ¬AppropriateFor x y ∧ ¬AppropriateFor x z"

(* Explanation 2: Combination vemurafenib and MEK inhibitor is unavailable for the patient *)
axiomatization where
  explanation_2: "∀x y z. Combination x ∧ Vemurafenib x ∧ MEKInhibitor x ∧ Patient y ⟶ ¬AvailableFor x y"

(* Explanation 3: The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAFV600 mutations irrespective of prior treatment with BRAF and/or MEK inhibitors *)
axiomatization where
  explanation_3: "∃x y z w e1 e2. Combination x ∧ Vemurafenib x ∧ Carboplatin x ∧ Paclitaxel x ∧ Patient y ∧ AdvancedMelanoma y ∧ BRAFV600 y ∧ Activity z ∧ Tolerated e1 ∧ Agent e1 x ∧ Demonstrates e2 ∧ Agent e2 x ∧ Agent e2 z ∧ PredominantlyIn y e2 ∧ IrrespectiveOf w e2 ∧ (BRAF w ∨ MEKInhibitors w)"

(* Explanation 4: Combination of vemurafenib with chemotherapy, such as carboplatin and paclitaxel, benefits patients with advanced melanoma and BRAFV600 mutations by improving treatment outcomes, specifically for those who have not been treated with BRAF and/or MEK inhibitors *)
axiomatization where
  explanation_4: "∃x y z w e1 e2. Combination x ∧ Vemurafenib x ∧ Chemotherapy x ∧ Carboplatin x ∧ Paclitaxel x ∧ Patient y ∧ AdvancedMelanoma y ∧ BRAFV600 y ∧ Outcomes z ∧ Benefit e1 ∧ Agent e1 x ∧ Agent e1 y ∧ Improve e2 ∧ Agent e2 x ∧ Agent e2 z ∧ SpecificallyFor y e2 ∧ ¬TreatedWith y w ∧ (BRAF w ∨ MEKInhibitors w)"

theorem hypothesis:
  assumes asm: "Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y"
  (* Hypothesis: Patient may benefit from combination vemurafenib and chemotherapy *)
  shows "∃x y e. Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y ∧ Benefit e ∧ Agent e x ∧ Agent e y"
proof -
  (* From the premise, we have known information about the patient, combination, vemurafenib, and chemotherapy. *)
  from asm have "Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y" by meson
  (* Explanation 4 provides that patients with advanced melanoma and BRAFV600 mutations benefit from combination of vemurafenib with chemotherapy. *)
  (* There is a logical relation Implies(E, D), which implies that patients who have not been treated with BRAF and/or MEK inhibitors benefit from the combination. *)
  (* Explanation 4 also states that this combination improves treatment outcomes, specifically for those who have not been treated with BRAF and/or MEK inhibitors. *)
  (* Therefore, we can infer that the patient may benefit from the combination vemurafenib and chemotherapy. *)
  then have "∃e. Benefit e ∧ Agent e x ∧ Agent e y" sledgehammer
  then show ?thesis <ATP>
qed

end
